Logo

Immunis, Inc.

Immunis has developed a novel method to grow human stem cells in clinically compliant conditions, direct them to become highly pure populations of defined immune system

Laguna Beach, CA, USA

One Liner

One Liner
Immunis has developed a novel method to grow human stem cells in clinically compliant conditions, direct them to become highly pure populations of defined immune system

What Problem We are Solving

Problem
Muscle wasting associated with age and immobilization causes a substantial decrease in muscle strength, size and ability of muscle movement. It is caused by a lack of activity, several diseases and in every person as a result of aging (sarcopenia). Most individuals begin to lose muscle mass after the age of thirty, adversely affecting levels of activity and quality of life. The surge in prevalence of chronic diseases and a rise in the geriatric population globally are major factors propelling the muscle wasting disorders market. This sector has attracted several large pharmaceutical companies. The effects of muscle immobilization atrophy in older populations are fast and measurable, resulting in well defined clinical outcome measures

About Us

About Us
We have a solution that prevents muscle atrophy, and reverses it in the aged. The muscle wasting market is $4-7BN, and THERE ARE NO APPROVED DRUGS FOR MUSCLE ATROPHY, with tremendous demonstrable interest by big pharma in this sector

Business Model

Business Model
Complete the current round, providing all necessary funding. Obtain Phase 3 approval in 2 years. Sell or IPO for investor return.

Competitive Advantage

Quote
Ours is the only drug to have been proven to prevent muscular atrophy with age or immobilization, and reverse muscle atrophy caused by age or immobilization. Our drug is very inexpensive to produce, and would be repeatedly taken.

Go-To Market Strategy

Business Strategy
This funding round will allow us to complete Phase 1 and 2 testing, and obtain a Phase 3 award. Over 90% of companies sell when they obtain a Phase 3 award, as our team has personally demonstrated. Thus, we plan to sell within 2-3 years, or IPO.

Competitive Analysis

Competitive Analysys
An FDA-Validated Emerging Sector A Large Market Opportunity Strong Interest by Large Pharmaceutical Companies No current competition in the commercial space

Competitor Website
x x
x x
x x

Networking

Networking
We are open to meeting up to grab a coffee, or just to chat. We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!

Share

Capital

Name Amount
Amount Raise To Date N/A

Valuation
N/A

Think a friend might be interested in this?

Enter their email to share it with them!

Thank you for the feedback!

We take all inquiries to heart and look forward to adding new features and finding out new ways to help.

We love feedback as much as you do.

We built this site for you.

Let us know how to make it better and what features you want going forward!